Curtis M. Rocca serves as Managing Partner of DCA Partners, responsible for all aspects of the organization, and also functions as a General Partner to the Firm’s affiliated private equity fund, DCA Capital Partners. Mr. Rocca is a seasoned chief executive with a background in leading high growth organizations from inception to exit.
Prior to DCA, Mr. Rocca was recruited by Burnham Securities of New York to be Chief Executive Officer of Dental Partners, Inc., a healthcare services roll-up based in Sacramento, CA, but with operations across the U.S. During his stint at Dental Partners, Mr. Rocca led the growth and operations of this multi-state healthcare consolidation from a standing start to over $30 million in revenues in 18 months, before driving negotiations for the Company’s sale in late 2000.
Prior to Dental Partners, Mr. Rocca was President, Chief Executive Officer, and Chairman of the Board of Bio-Dental Technologies Corp. (NASDAQ: BDTC). Under his leadership, Bio-Dental quickly became one of the nation’s fastest growing companies, as recognized by Business Week magazine. Mr. Rocca led the Company through several rounds of financing in both the private and public markets, a number of strategic acquisitions (and related integration thereof), and managed all investor relations activities and company operations. In 1997, Bio-Dental was purchased by Zila, Inc. (NASDAQ: ZILA). As a critical part of this transaction, Mr. Rocca successfully argued a technical point with the SEC, which caused the SEC staff members to reverse a previously issued position that would have otherwise killed the transaction. Bio-Dental’s share value increased over 50x during Mr. Rocca’s term as CEO. Following the successful close of the merger, Mr. Rocca remained a Director of Zila, Inc.
In 2002, Mr. Rocca was recruited by publicly traded Schick Technologies (NASDAQ: SIRO) in New York to join their Board of Directors to oversee their corporate restructuring following an extensive SEC investigation. While at Schick, he served as the Chair of the Compensation Committee, Audit Committee Financial Expert, and member of the Special Executive Committee overseeing ongoing communication and negotiations with the SEC. The turnaround was successful and the company was ultimately sold to German-based Sirona, Inc. During Mr. Rocca’s service on the Board, the company’s share price increased over 20x, from under $2 to over $40 per share.
Mr. Rocca has also been recognized as a regional finalist for Ernst & Young’s Enterpreneur of the Year award, and is an active supporter of the American Cancer Society and the Leukemia and Lymphoma Society.